Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 24Neoplasms 23Ovarian Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Breast Diseases 6Recurrence 5Medulloblastoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 4Neoplasms by Site 4Lymphoma, Mantle-Cell 4Liposarcoma 4Glioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

palbociclib 1exemestane 1Letrozole 1Hydroxychloroquine 1BID protein, human 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer × palbociclib × Clear all
NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡